Piroz Bahar

Mr. Piroz Bahar

University of Michigan Medical School, Ann Arbor, Michigan, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CNCharles B. Nguyen
Charles B. Nguyen
EOEugene Oh
Eugene Oh
PBPiroz Bahar
Piroz Bahar
UVUlka N. Vaishampayan
Ulka N. Vaishampayan
TETobias Else
Tobias Else
AAAjjai S. Alva
Ajjai S. Alva
Germline inactivation of the Von Hippel-Lindau (VHL) tumor suppressor is the defining hallmark in hereditary VHL disease and VHL-associated renal cell carcinoma (RCC). However, somatic VHL mutations are also observed in patients with sporadic RCC. Loss of function VHL mutations result in constitutive activation of hypoxia-inducible factor-2 alpha (HIF-2α), which leads to increased expression of HIF target genes that promote angiogenesis and tumor growth. As of 2023, belzutifan is currently the only approved HIF-2α inhibitor for both VHL-associated and sporadic metastatic RCC (mRCC). However, there is potential for resistance with HIF-2α inhibitors which warrants novel HIF-2α-targeting strategies. In this review, we discuss the potential resistance mechanisms with belzutifan and current clinical trials evaluating novel combinations of belzutifan with other targeted therapies and immune checkpoint inhibitors which may enhance the efficacy of HIF-2α targeting. Lastly, we also discuss newer generation HIF-2α inhibitors that are currently under early investigation and outline future directions and challenges with HIF-2α inhibitors for mRCC.

1 September 2025 in Urology Practice
Verified
Journal Article
Closed access
JSJulie R. Solomon
Julie R. Solomon
PBPiroz Bahar
Piroz Bahar
ABAndrew Bisenius
Andrew Bisenius
MDMiles Duncan
Miles Duncan
DPDrew K. Price
Drew K. Price
DSDouglas W. Storm
Douglas W. Storm
Evidence shows the 2014 American Urologic Association Cryptorchidism Guidelines have not influenced the use of ultrasonography prior to urologic evaluation or referral timing. We evaluated whether local indicators of healthcare access are associated with these quality-of-care indicators. Boys referred in 2013, 2015, and 2019 for cryptorchidism at four institutions were retrospectively analyzed. Local indicators of healthcare access were assessed by cross-referencing patient zip codes to the Rural Health Information and Health Resources and Service Administration websites. Using univariate generalized linear mixed models, we evaluated the association of geocoded factors to the likelihood of pre-evaluation sonography and mean age at referral. A total of 3,243 patients were evaluated. Boys from rural and designated health shortage areas were more likely to undergo sonography [OR 1.38, 95% CI 1.06-1.81 and OR 20.5, 95% CI 4.83-87.2, respectively] yet more likely to be referred at a younger age [OR 0.87, 95% CI 0.78-0.97 and OR 0.70, 95% CI 0.53-0.93]. Conversely, boys with private insurance [OR 0.48, 95% CI 0.27-0.86] and those residing near a referral center [OR 0.53, 95% CI 0.42-0.66] or from wealthier counties [OR 0.42 95% CI 0.30-0.59] were less likely to undergo sonography. Boys with cryptorchidism living in rural, poorer, and medically underserved areas were more likely to receive a pre-evaluation ultrasound yet were more likely to be referred to a pediatric urologist at a younger age than their counterparts. Drivers of guideline-adherent care may differ depending on the care component and local healthcare access availability.

9 October 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
EOEugene Oh
Eugene Oh
YCYe Chua
Ye Chua
PBPiroz Bahar
Piroz Bahar
MAMarie-Louise Accardo
Marie-Louise Accardo
XLXiaochen Li
Xiaochen Li
CNCharles B. Nguyen
Charles B. Nguyen

3 July 2025 in Journal of Endourology
Verified
Journal Article
Closed access
PBPiroz Bahar
Piroz Bahar
EOEugene Oh
Eugene Oh
KDKaran Desai
Karan Desai
MJMatthew Jordan
Matthew Jordan
MAMichael Ayenew
Michael Ayenew
AGArvin K. George
Arvin K. George
Introduction and Objectives: Assessing oncological success following focal ablation for prostate cancer (PCa) includes prostate-specific antigen (PSA) response and imaging. However, the value of protocol biopsy remains uncertain. Consensus recommendations include follow-up multiparametric MRI (mpMRI) and biopsy despite variable imaging quality, interpretation, and biopsy performance. We aim to determine mpMRI performance characteristics postablation for early in-field (within the ablation zone) failure following focal cryoablation (FC). Methods: Patients receiving FC from January 1, 2017, to April 21, 2023, at Michigan Medicine were enrolled in a multi-institutional, institutional review board-approved prospective registry. Per protocol, PSA, mpMRI, and ultrasound-MR fusion biopsy of the ablation bed were obtained at 6 to 12 months postablation. Residual PCa was suspected on mpMRI if there was persistent enhancement and impeded diffusion near the ablation zone colocalizing to the intended ablation target. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of postablation mpMRI for Gleason Grade Group (GG) ≥2 PCa were calculated. Chi-squared test was used to perform bivariate analysis. Results: A total of 76 patients underwent primary ablation, postablation mpMRI, and protocol biopsy. Eight patients underwent repeat cryoablation with postsalvage cryoablation mpMRI and biopsy ( N = 84 postablation events). Postablation mpMRI showed persistent PCa in 13.4% (11/84). Postablation biopsy showed GG ≥2 PCa in 7.1% (6/84) of target lesions. MpMRI sensitivity, specificity, PPV, and NPV for detecting untreated GG ≥2 PCa postablation were 83.3%, 92.3%, 45.5%, and 98.6%, respectively, with significant association between positive MRI and biopsy detection of GG ≥2 PCa ( p < 0.0001). The positive and negative likelihood ratios for residual disease detection were 10.8 and 0.18. Conclusion: Postablation mpMRI has a high sensitivity, NPV, and specificity for detecting untreated GG ≥2 PCa. If negative, near-term “protocol” biopsy may be safely avoided. Investigation into causes of false positive and negative postablation mpMRI will help identify those who warrant per-protocol biopsy.

11 June 2025 in Clinical Science
Verified
Journal Article
Open access
TYTeruhiko Yoshida
Teruhiko Yoshida
ZYZhi-Hong Yang
Zhi-Hong Yang
SAShinji Ashida
Shinji Ashida
ZYZu Xi Yu
Zu Xi Yu
SSShashi Shrivastav
Shashi Shrivastav
JKJeffrey Burnett Kopp
Jeffrey Burnett Kopp
In United States, six million individuals with sub-Saharan ancestry carry two APOL1 high-risk variants, which increase the risk for kidney diseases. Whether APOL1 high-risk variants increase other diseases under dyslipidemia remains unclear and requires further investigation. We characterized a mouse model to investigate the role of APOL1 in dyslipidemia and cardiovascular diseases (CVDs). Transgenic mice carrying APOL1 (G0 and G1 variants) on bacterial artificial chromosomes (BAC/APOL1 mice) were crossed with the apolipoprotein-E knock-out (ApoE-KO) dyslipidemia and atherosclerosis mouse model. The compound transgenic mice were evaluated for the impact of APOL1 on systemic phenotypes. ApoE-KO mice carrying APOL1-G0 and APOL1-G1 did not show differences in the extent of atherosclerotic lesions or aortic calcification, as evaluated by Sudan IV staining and radiographic examination, respectively. However, ~20% of ApoE-KO; BAC/APOL1-G1 mice developed hydrocephalus and required euthanasia. The hydrocephalus was communicating and likely was due to excess cerebrospinal fluid produced by the choroid plexus, where epithelial cells expressed APOL1. Single-nuclear RNA-seq of choroid plexus identified solute transporter up-regulation and mTORC2 pathway activation in APOL1-G1-expressing epithelial cells. Further, in the All of Us cohort, we found higher hydrocephalus prevalence among individuals with the APOL1-G1 variant in both recessive and dominant models, supporting the mouse findings. While APOL1-G1 expression in ApoE-KO mice did not worsen CVD phenotypes, we uncovered hydrocephalus as a novel APOL1 risk allele-mediated phenotype. These findings extend the spectrum of APOL1-associated pathologies.

10 August 2026 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
AHAva Harb
Ava Harb
PBPiroz Bahar
Piroz Bahar
SDStephanie Daignault-Newton
Stephanie Daignault-Newton
CSCaitlin Seibel
Caitlin Seibel
PRPaholo Barboglio Romo
Paholo Barboglio Romo
YZYu Zheng
Yu Zheng